Noteworthy, although IFN-α and epigenetic drugs in combination exert significant antitumor activity in both metastatic cells and CSCs, the traits of this response own some differences in quality and timing between the two types of CRC cells, suggesting the potential to activate selective signals in different components of the tumor mass. This evidence concerns the gene IFNA1 and neoplasm.